BPC-157 and Angiogenesis: The Evidence
BPC-157 for Tendon Injuries
VEGFR2 upregulation
BPC-157 increases VEGFR2 expression and internalization in endothelial cells, amplifying the angiogenic signal without raising VEGF ligand levels.
Hsieh et al., Journal of Molecular Medicine, 2017
Hsieh et al., Journal of Molecular Medicine, 2017
View as imageNew blood vessel formation, angiogenesis, is the rate-limiting step in tissue repair. A tendon, muscle, or ligament cannot heal faster than its blood supply can grow to deliver oxygen, nutrients, and immune cells to the damaged area. BPC-157, a 15-amino-acid peptide derived from human gastric juice, has demonstrated pro-angiogenic effects across multiple animal models and in vitro systems. The 2017 study by Hsieh and colleagues identified the primary mechanism: BPC-157 upregulates VEGFR2 (vascular endothelial growth factor receptor 2) on endothelial cells, making them more responsive to angiogenic signals without increasing VEGF ligand levels.[1] For broader context on BPC-157's tissue repair effects, see the pillar article on BPC-157 for tendon injuries.
Every study discussed in this article was conducted in animals or cell cultures. No human trial has specifically examined BPC-157's angiogenic effects. That limitation applies to the entire body of evidence below.
Key Takeaways
- BPC-157 increases VEGFR2 mRNA and protein expression in human endothelial cells without raising VEGF-A levels (Hsieh et al., 2017)
- In a chick chorioallantoic membrane assay, BPC-157 increased vessel density in vivo; in rats with hind limb ischemia, it accelerated blood flow recovery (Hsieh et al., 2017)
- BPC-157 activates the Src-Caveolin-1-eNOS pathway independently of VEGF, producing nitric oxide-mediated vasodilation in isolated rat aorta (Hsieh et al., 2020)
- In transected rat Achilles tendons, BPC-157 increased VEGF expression at the injury site and improved biomechanical healing outcomes (Brcic et al., 2009)
- A 2014 review concluded BPC-157 influences multiple aspects of vascular response to injury: endothelial repair, clotting, vasodilation, and new vessel growth (Seiwerth et al., 2014)
- BPC-157 improved ligament, muscle, and burn wound healing in rats, with angiogenesis proposed as a shared downstream mechanism across tissue types (multiple studies, 2001-2010)
The VEGFR2 Mechanism: Receptor Upregulation, Not Ligand Flooding
The most mechanistically detailed BPC-157 angiogenesis study was published by Hsieh and colleagues in the Journal of Molecular Medicine in 2017.[1] The study used human umbilical vein endothelial cells (HUVECs), chick chorioallantoic membrane (CAM) assays, and a rat hind limb ischemia model to characterize BPC-157's pro-angiogenic effects.
The key finding was specificity. BPC-157 increased mRNA and protein expression of VEGFR2 but not VEGF-A in endothelial cells. This distinction matters because VEGF-A is the growth factor ligand and VEGFR2 is the receptor that transduces the angiogenic signal. By upregulating the receptor rather than the ligand, BPC-157 amplifies the cell's sensitivity to existing VEGF signals rather than flooding the system with additional growth factor. This is a fundamentally different mechanism from therapeutic VEGF administration.
BPC-157 also promoted VEGFR2 internalization in endothelial cells. Receptor internalization is required for full activation of downstream signaling cascades, including the PI3K-Akt-eNOS pathway that produces nitric oxide (NO). When the researchers blocked internalization with dynasore (an endocytosis inhibitor), BPC-157's angiogenic effects were attenuated, confirming that receptor trafficking is part of the mechanism.
In the CAM assay, BPC-157 increased vessel density in a dose-dependent manner. In rats with surgically induced hind limb ischemia, BPC-157 treatment accelerated recovery of blood flow to the ischemic limb as measured by laser Doppler scanning. These functional outcomes demonstrate that the in vitro receptor upregulation translates into actual vessel formation in living tissue.
The Nitric Oxide Connection: A Second Pathway
Three years after the VEGFR2 study, the same research group published a follow-up examining BPC-157's effects on vasomotor tone and the Src-Caveolin-1-eNOS signaling pathway.[2]
This study demonstrated that BPC-157 produces concentration-dependent vasodilation in isolated rat aorta. The vasodilation was endothelium-dependent, meaning it required intact endothelial cells to function. Removing the endothelium eliminated the effect, confirming that BPC-157 acts on endothelial cells rather than directly on vascular smooth muscle.
The mechanism involves the Src-Caveolin-1-eNOS pathway, which is independent of VEGF. Caveolin-1 normally inhibits eNOS by holding it in an inactive state within caveolae (small invaginations in the cell membrane). BPC-157 activates Src kinase, which phosphorylates caveolin-1 and releases eNOS from inhibition. The freed eNOS produces nitric oxide, which causes vasodilation and promotes angiogenesis.
This gives BPC-157 two parallel routes to angiogenesis: a VEGF-dependent pathway through VEGFR2 upregulation and a VEGF-independent pathway through Src-Caveolin-1-eNOS activation. The sibling article on BPC-157 and nitric oxide covers the NO pathway in greater detail.
Angiogenesis in Muscle and Tendon Healing
The earliest direct evidence for BPC-157's angiogenic effects in tissue healing came from Brcic and colleagues in 2009.[3] They studied angiogenesis during healing of transected rat Achilles tendons and crushed quadriceps muscles, comparing BPC-157 treatment to controls.
VEGF expression was increased at injury sites in BPC-157-treated animals. The peptide promoted formation of new blood vessels in the healing zone, and this correlated with improved biomechanical outcomes. Importantly, BPC-157 appeared to modulate rather than simply increase angiogenesis. The vessel formation was organized and functional rather than chaotic, a distinction that matters because disorganized angiogenesis (as seen in tumors) does not support tissue repair.
Staresinic and colleagues had previously shown in 2003 that BPC-157 accelerated transected Achilles tendon healing and directly stimulated tendocyte proliferation in vitro.[4] Their work demonstrated both improved biomechanical properties and better histological organization in BPC-157-treated tendons. While this study focused on the tendon cells themselves, the improved healing was consistent with enhanced blood supply to the repair site.
The Blood Vessel Review: Vascular Effects Beyond Angiogenesis
Seiwerth and colleagues published a comprehensive review in 2014 titled "BPC 157 and blood vessels," cataloging the peptide's effects across multiple vascular injury models.[5] The review documented effects on:
- Endothelial damage repair: BPC-157 accelerated restoration of damaged endothelium in multiple animal models
- Thrombosis: The peptide influenced clotting cascades at injury sites
- Vasoconstriction and vasodilation: BPC-157 modulated vascular tone depending on the pathological context
- New vessel formation: Consistent pro-angiogenic effects across tissue types
- Edema reduction: BPC-157 reduced fluid accumulation around vascular injury sites
The review's conclusion was that BPC-157 acts as a comprehensive vascular modulator rather than a simple angiogenic agent. It does not just grow new vessels; it influences the entire vascular response to injury. This broader vascular activity may explain why BPC-157 shows healing effects across such diverse tissue types, from tendons and ligaments to liver and brain tissue.
Healing Across Tissue Types: The Angiogenic Common Thread
If angiogenesis is a shared mechanism underlying BPC-157's tissue repair effects, then the peptide's healing activity in different tissues should correlate with vascular improvement. The animal literature is consistent with this hypothesis.
Cerovecki and colleagues showed in 2010 that BPC-157 improved medial collateral ligament healing in rats, with better biomechanical strength and histological organization across 90 days of observation.[6] The study used intraperitoneal, oral (in drinking water), and topical (cream) administration, and all routes showed benefit. For more detail on these results, see BPC-157 and ligament healing.
Novinscak and colleagues demonstrated in 2008 that BPC-157 accelerated healing of muscle crush injury in rats with improved functional recovery and histological regeneration.[7] Crushed muscle faces a severe angiogenic challenge because the existing vasculature is destroyed and must be rebuilt before muscle fibers can regenerate. The sibling article on BPC-157 muscle injury recovery covers this evidence in detail.
Pevec and colleagues showed in 2010 that BPC-157 could improve muscle healing even when impaired by systemic corticosteroid administration.[8] Corticosteroids are known to suppress angiogenesis and impair wound healing, so BPC-157's ability to counteract this suppression is consistent with a pro-angiogenic mechanism overriding steroid-induced vascular inhibition.
Mikus and colleagues found in 2001 that topical BPC-157 cream accelerated burn wound healing in mice, with faster re-epithelialization and wound contraction.[9] Burns destroy the dermal vasculature completely, making angiogenesis essential for wound bed preparation before skin regeneration can occur.
The Gastric Connection and Broader BPC-157 Biology
BPC-157 is a fragment of a protein found in human gastric juice. Sikiric and colleagues documented in their 2006 review that the peptide has been in clinical trials for inflammatory bowel disease (IBD) under the designations PL-10, PLD-116, and PL 14736.[10] The review noted that BPC-157's cytoprotective and healing activities extend from the gut to diverse organ systems, and proposed angiogenesis as one of several mechanism clusters (alongside NO system modulation, prostaglandin regulation, and growth factor activation) that explain its broad therapeutic profile.
Vuksic and colleagues expanded this in 2007, adding evidence that BPC-157 promotes angiogenesis in the context of intestinal anastomosis healing, fistula closure, and stricture prevention.[11] For cross-cluster context on BPC-157's gut-healing effects, see BPC-157 for inflammatory bowel disease and BPC-157 and the gut-brain axis.
How BPC-157 Angiogenesis Compares to Other Pro-Angiogenic Approaches
BPC-157's angiogenic mechanism is unusual in the peptide therapeutics landscape. Most pro-angiogenic therapies under investigation work by delivering VEGF-A or other growth factors directly to ischemic tissue. Gene therapy approaches encode VEGF in viral vectors. Recombinant protein approaches deliver VEGF-A by injection. Both strategies have produced disappointing results in clinical trials for peripheral artery disease and myocardial ischemia, largely because flooding tissue with VEGF creates leaky, disorganized vessels rather than functional vasculature.
BPC-157's receptor-upregulation approach is mechanistically distinct. By increasing VEGFR2 density rather than VEGF-A concentration, BPC-157 amplifies the tissue's response to its own physiological VEGF signals. This could theoretically produce more organized angiogenesis because the spatial and temporal regulation of endogenous VEGF secretion is preserved. The Brcic 2009 tendon healing study supports this interpretation: blood vessels formed in BPC-157-treated tendons appeared organized rather than chaotic.[3]
The dual-pathway activation (VEGF-dependent via VEGFR2 and VEGF-independent via Src-Caveolin-1-eNOS) also distinguishes BPC-157 from single-pathway angiogenic agents. Whether this represents a therapeutic advantage or simply a broader mechanism with more potential for off-target effects remains untested. The BPC-157 and hepatic ischemia article examines how these vascular mechanisms may apply to liver blood flow specifically.
What the Evidence Cannot Tell Us
The angiogenesis data for BPC-157 is mechanistically rich but clinically unproven. Several gaps remain:
No human angiogenesis data exists. Every study described above used rats, mice, chicks, or cell cultures. Whether BPC-157 upregulates VEGFR2 or activates the Src-Caveolin-1-eNOS pathway in human tissue in vivo is unknown.
Dosing for angiogenic effect is undefined. Animal studies use a range of doses and routes. The dose required to produce meaningful angiogenic effects in humans has never been established. The relationship between systemic BPC-157 levels and local tissue angiogenesis has not been characterized.
Long-term vascular effects are unstudied. Promoting angiogenesis is desirable in healing tissue. It is undesirable in tumors, where new blood vessels feed cancer growth. No study has examined whether chronic BPC-157 administration affects tumor angiogenesis, vascular remodeling, or other long-term vascular outcomes.
The receptor for BPC-157 has not been definitively identified. While BPC-157 upregulates VEGFR2 and activates Src, the initial binding target through which BPC-157 enters the signaling cascade remains unknown. Without knowing the primary receptor, the full mechanism cannot be mapped, and off-target effects cannot be predicted.
The BPC-157 overview article and the sibling article on BPC-157's effect on fibroblasts provide additional context on these limitations.
The Bottom Line
BPC-157 promotes angiogenesis through at least two identified pathways: VEGFR2 upregulation (amplifying sensitivity to existing VEGF signals) and Src-Caveolin-1-eNOS activation (producing nitric oxide independently of VEGF). These mechanisms have been demonstrated in cell cultures, chick embryo assays, and rat ischemia models. The pro-angiogenic effect correlates with improved healing across tendons, muscles, ligaments, and burn wounds in animal studies. No human trial has examined BPC-157 angiogenesis, and the peptide's primary receptor remains unidentified.